CEFUROXIME AXETIL tablet, film coated

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

CEFUROXIME AXETIL (UNII: Z49QDT0J8Z) (CEFUROXIME - UNII:O1R9FJ93ED)

Available from:

Wockhardt Limited

INN (International Name):

CEFUROXIME AXETIL

Composition:

CEFUROXIME 125 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Cefuroxime axetil tablets, USP are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of Streptococcus pyogenes . Limitations of Use - The efficacy of cefuroxime axetil tablets, USP in the prevention of rheumatic fever was not established in clinical trials. - The efficacy of cefuroxime axetil tablets, USP in the treatment of penicillin-resistant strains of Streptococcus pyogenes has not been demonstrated in clinical trials. Cefuroxime axetil tablets, USP are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of Streptococcus  pneumoniae , Haemophilus influenzae (including β- lactamase-producing strains), Moraxella catarrhalis (including β- lactamase-producing strains), or Streptococcus pyogenes. Cefuroxime axetil tablets, USP are indicated for the treatment of adu

Product summary:

Cefuroxime axetil tablets USP, 125 mg of cefuroxime as cefuroxime axetil, are white film-coated, round-shaped biconvex unscored tablets embossed with W920 on one side and plain on other side as follows: 20 Tablets/ Bottle                    NDC 64679-920-01 60 Tablets/ Bottle                    NDC 64679-920-02 Cefuroxime axetil tablets USP, 250 mg of cefuroxime as cefuroxime axetil, are white film-coated, round-shaped biconvex unscored tablets embossed with W921 on one side and plain on other side as follows: 20 Tablets/ Bottle                    NDC 64679-921-01 60 Tablets/ Bottle                    NDC 64679-921-02 Cefuroxime axetil tablets USP, 500 mg of cefuroxime as cefuroxime axetil, are white film-coated, round-shaped biconvex unscored tablets embossed with W922 on one side and plain on other side as follows: 20 Tablets/ Bottle                    NDC 64679-922-01 60 Tablets/ Bottle                    NDC 64679-922-02 Store at 20° - 25°C (68° - 77°F). Replace cap securely after each opening.

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

CEFUROXIME AXETIL- CEFUROXIME AXETIL TABLET, FILM COATED
WOCKHARDT LIMITED
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CEFUROXIME AXETIL TABLETS SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CEFUROXIME AXETIL
TABLETS.
CEFUROXIME AXETIL TABLETS, USP, FOR ORAL USE
INITIAL U.S. APPROVAL: 1987
INDICATIONS AND USAGE
Cefuroxime axetil is a cephalosporin antibacterial drug indicated for
the treatment of the following infections due to
susceptible bacteria: (1)
Pharyngitis/tonsillitis (adults and pediatric patients) (1.1)
Acute bacterial otitis media (pediatric patients) (1.2)
Acute bacterial maxillary sinusitis (adults and pediatric patients)
(1.3)
Acute bacterial exacerbations of chronic bronchitis and secondary
bacterial infections of acute bronchitis (adults and
pediatric patients 13 years and older) (1.4)
Uncomplicated skin and skin-structure infections (adults and pediatric
patients 13 years and older) (1.5)
Uncomplicated urinary tract infections (adults and pediatric patients
13 years and older) (1.6)
Uncomplicated gonorrhea (adults and pediatric patients 13 years and
older) (1.7)
Early Lyme disease (adults and pediatric patients 13 years and older)
(1.8)
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of cefuroxime axetil tablets and other
antibacterial drugs, cefuroxime axetil tablets should be used only to
treat or prevent infections that are proven or strongly
suspected to be caused by bacteria.
DOSAGE AND ADMINISTRATION
Tablets and oral suspension are not bioequivalent and are therefore
not substitutable on a milligram-per-milligram
basis. (2.1)
Administer tablets with or without food. (2.2)
Administer cefuroxime axetil tablets as described in the dosage
guidelines. (2.2)
Dosage adjustment is required for patients with impaired renal
function. (2.5)
ADULT PATIENTS AND PEDIATRIC PATIENTS DOSAGE
GUIDELINES FOR CEFUROXIME AXETIL TABLETS
INFECTION
DOSAGE
DURATION (DAYS)
ADULTS AND ADOLESCENTS